Two studies showed a correlation of PTEN positivity with more advanced clinical stage of breast cancer without predictive value for the outcome of trastuzumab-based treatment in the neoadjuvant [30], adjuvant and metastatic setting [31]. This evidence concerns the gene PTEN and breast carcinoma.